The global cardiogenic shock treatment market is expected to increase at a compound annual growth rate (CAGR) of 7% between 2023 and 2033, from US$ 0.9 billion in 2023 to US$ 1.77 billion by 2033. With a 3.5% compound annual growth rate, the market for cardiogenic shock treatment grew between 2018 and 2022.

Cardiogenic shock is a life-threatening condition that occurs when the heart is unable to pump enough blood to meet the body’s needs. It is typically caused by a severe heart attack, heart failure, or other heart-related conditions. Prompt and aggressive treatment is crucial in managing cardiogenic shock and improving the chances of survival. The primary goal of treatment is to restore blood flow to the vital organs and stabilize the heart.

Seize Excellence Today: Claim Your Sample for Unmatched Efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16771

One of the mainstays of Cardiogenic Shock Treatment is providing immediate and effective circulatory support. This often involves the use of medications such as vasopressors, which constrict blood vessels and increase blood pressure, and inotropic agents, which help strengthen the heart’s pumping action. In severe cases, mechanical devices like intra-aortic balloon pumps or ventricular assist devices may be used to assist the heart’s function and enhance blood flow.

Additionally, reperfusion therapy plays a critical role in the treatment of cardiogenic shock caused by a heart attack. This involves restoring blood flow to the blocked coronary artery responsible for the heart attack. Reperfusion therapy can be achieved through percutaneous coronary intervention (PCI), a procedure in which a catheter is used to open the blocked artery and restore blood flow, or through thrombolytic therapy, which involves the administration of clot-dissolving medications. The choice between PCI and thrombolytic therapy depends on the patient’s condition, available resources, and the time since the onset of symptoms.

Key Takeaways:

• From 2018 to 2022, the Cardiogenic Shock Therapies market increased at a CAGR of 3.5%.
• From 2023 to 2033, the market for Cardiogenic Shock Treatments is projected to expand at a 7% CAGR.
• The market for treatments for cardiogenic shock is anticipated to reach US$ 1.77 billion by 2033.
• The hospital sector holds the biggest market share, per the FMI research.
• For Cardiogenic Shock Therapies, North America is predicted to have a 40% market share.
• With a share of 20% throughout the projection period, it is expected that the East & South Asia market would grow considerably. 

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Cardiogenic Shock Treatments.” says an FMI analyst

Market Competition

Key players in the market include companies such as Getinge AB, Par Pharmaceutical, Abbott, Viatris Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Terumo Corporation, Medtronic, AbioMed, Astrazeneca along with healthcare providers and technology companies among other global players.

• In October 2022, the American Heart Association established the Cardiogenic Shock Registry, powered by Get with The Guidelines®, to provide a foundation for researchers, clinicians, and regulators to better understand the clinical symptoms, treatment patterns, and outcomes of different types of shock. The registry builds on over two decades of experience with the Get with The Guidelines® platform and will inform the medical community on how to best treat cardiogenic shock. The steering committee of the registry includes experts from leading academic surgeons and cardiologists, as well as representatives from the U.S. Food & Drug Administration and the US Centers for Medicare & Medicaid Services, who provide guidance on establishing and managing the data in the registry.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Cardiogenic Shock Treatments market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Treatment Type, End-User & Region.

Key Segments:

Treatment Type:

• In-Vitro Test Kits
• Drugs
• Devices

End- User:

• Cardiac Catheterization Labs
• Hospitals
• Ambulatory Surgical Centres